Although no therapy has been yet approved to date, systemic administration of recombinant human (rhu) IL-10 has been tested in multiple clinical trials for the treatment of autoimmune and immune-mediated inflammatory diseases (including inflammatory bowel disease, psoriasis, Crohn’s disease, rheumatoid arthritis, ulcerative colitis, pancreatitis), tissue damage, and chronic infectious diseases (such as chronic hepatitis C), due to its anti-inflammatory, wound repairing and anti-fibrotic functions, respectively (191–194). The gene discussed is IL10; the disease is rheumatoid arthritis.